Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.70 |
| ▸ | GSK3B | P49841 | 2/20 | 0.70 |
| ▸ | MAPK8 | P45983 | 9/20 | 0.53 |
| ▸ | TYRO3 | Q06418 | 6/20 | 0.53 |
| ▸ | MERTK | Q12866 | 6/20 | 0.53 |
| ▸ | FLT3 | P36888 | 5/20 | 0.53 |
| ▸ | GAS6 | Q14393 | 5/20 | 0.53 |
| ▸ | AXL | P30530 | 3/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | ULK1 | O75385 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385264 | 1.00 | GSK3A (0.70) | GSK3AGSK3BMAPK8TYRO3MERTK | |
| SCHEMBL5806595 | 0.96 | GSK3B (0.74) | GSK3AGSK3BMAPK8TYRO3MERTK | |
| SCHEMBL17544767 | 0.89 | GSK3B (0.64) | GSK3AGSK3BMAPK8CDK2PRKCQ | |
| SCHEMBL1961567 | 0.87 | GSK3A (0.64) | GSK3AGSK3BMAPK8TYRO3MERTK | |
| SCHEMBL6890352 | 0.87 | GSK3A (0.64) | GSK3AGSK3BMAPK8TYRO3MERTK | |
| SCHEMBL14685715 | 0.87 | GSK3A (0.64) | GSK3AGSK3BMAPK8TYRO3MERTK | |
| SCHEMBL14589028 | 0.82 | GSK3A (0.57) | GSK3AGSK3BMAPK8AXLCDK2 | |
| SCHEMBL1265079 | 0.82 | GSK3A (0.57) | GSK3AGSK3BMAPK8AXLCDK2 | |
| SCHEMBL1265078 | 0.82 | GSK3A (0.57) | GSK3AGSK3BMAPK8AXLCDK2 | |
| SCHEMBL28657769 | 0.81 | GSK3A (0.53) | GSK3AGSK3BCDK2PRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725450-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160039822-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2016-02-11 | — | — | US | disclosed |
| US-9187479-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140206697-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-07-24 | — | — | US | disclosed |
| EP-2289893-B1 | Haloaryl substituted aminopurines for use in treatment | SIGNAL PHARM LLC (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2112151-B1 | Haloaryl substituted aminopurines for use in treatment | SIGNAL PHARM LLC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20130225564-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8440661-B2 | Methods of modulating inflammatory cell recruitment and gene expression using haloaryl substituted aminopurines | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2010186-B1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8101588-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-7723340-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090312320-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HALOARYL SUBSTITUTED AMINOPURINES OR COMPOSITIONS THEREOF | SIGNAL PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090275564-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | ALBERS RONALD J | 2009-11-05 | — | — | US | disclosed |
| EP-2112151-A2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-1838710-B1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-7521446-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2009-04-21 | — | — | US | disclosed |
| US-20080021048-A1 | Methods of treatment and prevention using haloaryl substituted aminopurines | SIGNAL PHARMACEUTICALS, LLC | 2008-01-24 | — | — | US | disclosed |
| US-20070060598-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20060287344-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | PHARMACOPEIA, LLC | 2006-12-21 | — | — | US | disclosed |
| WO-2006091737-A1 | MODULATORS OF GSK-3 ACTIVITY | KEMIA, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287344-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | TPMT, MGMT, HPRT1 | GSK3A 104/4885GSK3B 41/4885MAPK8 15/4885 |
| US-20090275564-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | GSK3A 140/4885GSK3B 68/4885MAPK8 26/4885 |
| US-20140206697-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | GSK3A 140/4885GSK3B 68/4885MAPK8 26/4885 |
| US-20130225564-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | GSK3A 140/4885GSK3B 68/4885MAPK8 26/4885 |
| US-20080021048-A1 | Methods of treatment and prevention using haloaryl substituted aminopurines | TPMT, MGMT, SMAD3 | GSK3A 188/4885GSK3B 94/4885MAPK8 11/4885 |
| US-20160039822-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | GSK3A 140/4885GSK3B 68/4885MAPK8 26/4885 |
| US-20090312320-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HALOARYL SUBSTITUTED AMINOPURINES OR COMPOSITIONS THEREOF | TPMT, MGMT, SMAD3 | GSK3A 102/4885GSK3B 53/4885MAPK8 24/4885 |
| US-20070060598-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | TPMT, MGMT, HPRT1 | GSK3A 140/4885GSK3B 68/4885MAPK8 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.